07/10/2014 - 7:41pm

The bath and body segment has benefited from near universal usage as consumers use these products in their daily personal hygiene routine.

07/10/2014 - 7:40pm

Benefiting from a heightened focus on healthier, youthful-looking skin and a flawless complexion, sales within the facial cleanser segment are on the upswing.

07/10/2014 - 7:40pm

When it comes to skin care, facial anti-aging potions still reign, as women continue their quest for younger, healthier looking skin.

07/10/2014 - 7:40pm

Lift, smooth, de-wrinkle and firm. This is the desired effect of not only facial anti-agers, but also those formulas for the body, as aging women yearn to turn back the hands of time below the neck.

07/10/2014 - 7:40pm

While sales of heat and ice packs are relatively flat — the category generated slight growth of 0.2% to $235.9 million for the 52 weeks ended April 20 across total U.S. multi-outlets, according to IRI — there has been some positive momentum within the category.

07/10/2014 - 7:40pm

The first-aid tape and bandage business is a relatively stable category without a lot of dramatic sales swings.

07/10/2014 - 7:40pm

The same weather factors that are boosting allergy sales as the allergy season is extended may be having a substantial impact on the sales of anti-itch ointments, up 10% to $528.2 million across U.S. multi-outlets for the 52 weeks ended April 20, according to IRI, and insect bite treatments, which totaled $13.6 million and were up 19.4% over the same period.

07/10/2014 - 7:39pm

Overall, the intimacy health category generated more than $870 million in sales, trending up in the low single-digits. Sales of condoms, the largest piece of the business, totaled $380.7 million across total U.S. multi-outlets for the 52 weeks ended April 20, and was down slightly by 1.8%. The growth is coming out of the personal lubricant ($213.4 million, up 2.9%) and emergency contraceptive ($253.2 million, up 12.3%) sectors.

07/10/2014 - 7:39pm

As lifetime earnings for pharmaceuticals decrease, commercialization expenses increase and payers tighten their belts on reimbursement, life science companies will be faced with shrinking margins over the next few years. In order to maintain basic operating margin levels and continue investing in research and development at current levels, life science manufacturers will be forced to reduce costs by more than $35 billion by 2017, according to results from a new survey of 70 life science organizations from the IMS Institute for Healthcare Informatics.